Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (53)

2023

  1. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  2. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

    Journal of medical economics, Vol. 26, Núm. 1, pp. 445-453

  3. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

    BMC Pulmonary Medicine, Vol. 23, Núm. 1

  4. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

  5. Possible heart failure caused by osimertinib in a lung cancer patient

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 4, pp. 1015-1020

2022

  1. A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

    Frontiers in Oncology, Vol. 12

  2. A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital

    Frontiers in Public Health, Vol. 10

  3. Análisis coste-utilidad de venetoclax en combinación con obinutuzumab como tratamiento de primera línea de la leucemia linfocítica crónica en España

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 3, pp. 121-132

  4. Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer

    Frontiers in Oncology, Vol. 12

  5. Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare

    Frontiers in Immunology, Vol. 13

  6. Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 47, Núm. 12, pp. 2020-2029

  7. Implantación de una metodología para evaluar patient‑reported outcomes en pacientes con cáncer de pulmón: Protocolo del estudio PeOpLe (Patient‑reported Outcomes in Lung cancer )

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 4, pp. 265-269

  8. Implementation and evaluation of a home pharmaceutical care model through Telepharmacy

    Farmacia Hospitalaria, Vol. 46, pp. 36-46

  9. Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility

    International Journal of Hematology, Vol. 115, Núm. 1, pp. 61-68

  10. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

    Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119

  11. Mobile Apps for Hematological Conditions: Review and Content Analysis Using the Mobile App Rating Scale

    JMIR mHealth and uHealth, Vol. 10, Núm. 2

  12. Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App

    Frontiers in Oncology, Vol. 12

2021

  1. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

    Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681

  2. COVID-19 in hospitalised patients in Spain: a cohort study in Madrid

    International Journal of Antimicrobial Agents, Vol. 57, Núm. 2

  3. Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: Costecat Study

    International journal of environmental research and public health, Vol. 18, Núm. 2